Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer
- Authors:
- Published online on: December 10, 2013 https://doi.org/10.3892/mco.2013.223
- Pages: 212-218
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including platinum and taxanes. The aim this study was to investigate the degree of platinum sensitivity in patients with relapsed epithelial ovarian cancer according to the treatment‑free interval (TFI) and the histological tumor type. The medical records of 405 patients diagnosed with stage III̸IV ovarian cancer, including 107 patients who relapsed after attaining a clinical complete response with first‑line treatment, were retrospectively reviewed. The degree of platinum sensitivity was assessed by comparing the progression‑free survival (PFS) following the second‑line treatment. in patients with serous̸endometrioid adenocarcinoma who were treated with platinum following relapse, there were significant differences in the PFS between the following groups of patients: those who relapsed within 6 months and those who relapsed between 6 and 12 months; those who relapsed between 6 and 12 months and those who relapsed between 12 and 18 months; and those who relapsed between 12 and 18 months and those who relapsed after 18 months. By contrast, in patients with clear cell̸mucinous adenocarcinoma who were treated with platinum following a relapse, there were no significant differences in the PFS between patients who relapsed within 6 months and those who relapsed between 6 and 12 months, while there were significant differences in the PFS between those who relapsed between 6 and 12 months and those who relapsed after 12 months. With regard to the patients who relapsed after 12 months, the PFS of those with clear cell̸mucinous adenocarcinoma was significantly shorter compared with the PFS of those with serous̸endometrioid adenocarcinoma. Therefore, we considered it justified to classify patients with clear cell̸mucinous adenocarcinoma who relapsed within 12 months as platinum‑resistant and those who relapsed after 12 months as platinum‑sensitive.
